Trial Search Results
MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
This research study tests a new medicine for mobilizing stem cells so they can be collected and used for autologous stem cell transplant for treatment of multiple myeloma. MGTA-145, the new medicine, will be given with plerixafor.
Stanford is currently not accepting patients for this trial.
- Drug: MGTA-145
- Drug: Plerixafor
- Diagnosis of multiple myeloma per the International Myeloma Working Group (IMWG)
- Eligible for ASCT per institutional guidelines
- Within one year of start of myeloma therapy
- Cardiac and pulmonary status sufficient to undergo apheresis and transplantation per
institutional transplant guidelines.
- Calculated creatinine clearance > 30 mL/min according to the Modification of Diet in
Renal Disease (MDRD) formula.
- Absolute neutrophil count > 1500 x106/L and platelets > 100,000 x106/L
- Ability to understand and the willingness to sign a written informed consent document.
- Agreement to use an approved form of contraception for male patients or female
patients of childbearing potential.
- History of prior stem cell transplant for multiple myeloma or other indications
- Planned tandem stem cell transplant
- Prior history of failure to collect HSCs.
- Liver function tests: Total bilirubin >1.5x upper limit of normal (ULN) in the absence
of a documented history of Gilbert's syndrome and/or aspartate aminotransferase
(AST)/alanine aminotransferase (ALT) > 3x ULN.
- Known allergy to MGTA-145 or plerixafor.
- Lifetime exposure to lenalidomide or another immunomodulatory drug greater than 6
cumulative months of treatment i.e more than six 28-day cycles or more than eight
- Pregnant or lactating women.
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study